The U.S. Food and Drug Administration has delayed reviews of several drugs selected for the Trump administrations new ...
FDA delayed fast-track reviews for multiple drugs after safety and efficacy concerns, including adverse events and a reported ...
The FDA postponed reviews for two drugs in the Trump administration's fast-track program due to safety and efficacy concerns.
The FDA has delayed reviews of drugs under its fast-track program due to safety and efficacy concerns, including trial data issues and adverse events. This includes Disc Medicine's rare blood disorder ...
Nanjing Leads Biolabs Co., Ltd. (HKE: 9887) ("Leads Biolabs" or the "Company") today announced that Opamtistomig (LBL-024), its core investigational PD-L1/4-1BB bispecific antibody, has been granted ...
The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.
The US Food and Drug Administration (FDA) has granted Fast Track Designation to Complement Therapeutics’ CTx001, the ...
The FDA has granted fast track designation to a vectorized antibody that targets RNA-binding proteins characteristic of ...
The Food and Drug Administration announced on Thursday the first round of experimental drugs to be included in a priority voucher program. This FDA initiative is designed to expedite drug review ...
CAMBRIDGE, Mass., Sept. 30, 2025 /PRNewswire/ -- Clear Scientific Inc., a clinical stage biopharmaceutical company focused on the development of first-in-class small molecules to reverse acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback